Figure 2.
Percentages of OX40+, IL-9+ CD4+ T cells at baseline and after exposure to branded and biosimilar infliximab. * p < 0.05, ** p <0.01.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.